Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmigeneROCO:7595 -0.54%58 EV-to-EBITDA is -90.35 as of Sep. 06, 2026. GuruFocus rates ROCO:7595 with a GF Score™ of 58/100 and a GF Value™ of NT$20.43 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 122 Medical Diagnostics & Research companies, Pharmigene ranks worse than 819671.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pharmigene's enterprise value is NT$1,226.1 Mil.
Pharmigene's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-13.6 Mil. Therefore, Pharmigene's EV-to-EBITDA for today is -90.35.
The historical rank and industry rank for Pharmigene's EV-to-EBITDA or its related term are showing as below:
ROCO:7595'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -97.95 Med: -29.01 Max: 238.04
Current: -90.35
During the past 9 years, the highest EV-to-EBITDA of Pharmigene was 238.04. The lowest was -97.95. And the median was -29.01.
ROCO:7595's EV-to-EBITDA is ranked worse than 100% of 122
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.23
vs ROCO:7595: -90.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pharmigene's share price for today is NT$7.31.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharmigene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-1.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Pharmigene's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7595 vs TMO, DHR, NTRA: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Pharmigene's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmigene EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pharmigene's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pharmigene's EV-to-EBITDA falls into.
Pharmigene's current Enterprise Value is NT$1,226.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharmigene's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-13.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmigene (ROCO:7595) has a EV-to-EBITDA of -90.35 as of Sep. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pharmigene. According to the industry distribution chart, Pharmigene ranks #999999 out of 122 companies in the Medical Diagnostics & Research industry.
Is Pharmigene's EV-to-EBITDA too high?
Pharmigene's current EV-to-EBITDA is -90.35. Based on the distribution chart, Pharmigene ranks #999999 out of 122 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pharmigene has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharmigene's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pharmigene ranks #999999 out of 122 companies for EV-to-EBITDA. This places Pharmigene in the lower half of its industry. The industry median EV-to-EBITDA is 16.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.23, based on 122 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pharmigene. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmigene's current EV-to-EBITDA is -90.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmigene stock overvalued right now?
Based on GuruFocus' analysis, Pharmigene (ROCO:7595) is currently considered Possible Value Trap. The stock's GF Value™ is NT$20.43, compared to a current price of NT$7.31 — trading 64.2% below its estimated fair value. The current EV-to-EBITDA is -90.35. Pharmigene's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Pharmigene (ROCO:7595), the current EV-to-EBITDA is -90.35 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmigene (ROCO:7595) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmigene stock appears to be undervalued.
The current stock price of NT$7.31 is trading 64.2% below its estimated GF Value™ of NT$20.43.
GuruFocus considers Pharmigene to be Possible Value Trap.
Key valuation signals for ROCO:7595:
EV-to-EBITDA: -90.35
GF Value™: NT$20.43 vs. price of NT$7.31 (64.2% below fair value)
No single metric tells the full story. See the ROCO:7595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmigene Inc is engaged in the development and sales of pharmaceutical genetic diagnostic products. Also, the company provides medical and drug testing services and equipment.
58GF Score
Get the complete analysis for ROCO:7595
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7595 has been successfully added to your 
